Cover Image

Call to action: Understanding the differences in the use of SGLT-2 inhibitors and GLP-1 receptor agonists

Cardiovascular disease remains one of the most prominent global health problems and has been demonstrated to disproportionally affect certain communities. Despite an increasing collective effort to improve health inequalities, a multitude of disparities continue to affect cardiovascular outcomes. Am...

Full description

Saved in:

Bibliographic Details
Main Authors:	Apurva Khedagi (Author), Cara Hoke (Author), Michelle Kelsey (Author), Andrea Coviello (Author), W. Schuyler Jones (Author), Larry R. Jackson, II (Author), Manesh R Patel (Author), Rob W. McGarrah (Author), Neha J Pagidipati (Author), Nishant P. Shah (Author)
Format:	Book
Published:	Elsevier, 2023-03-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Race and ethnicity and pharmacy dispensing of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetesResearch in context
by: Luis A. Rodriguez, et al.
Published: (2024)

Anti-Inflammation and Anti-Oxidation: The Key to Unlocking the Cardiovascular Potential of SGLT2 Inhibitors and GLP1 Receptor Agonists
by: Veronika A. Myasoedova, et al.
Published: (2023)

Optimizing cardiometabolic risk in people living with human immunodeficiency virus: A deep dive into an important risk enhancer
by: Elizabeth A. Kobe, et al.
Published: (2024)

GLP-1 agonists in treatment of obesity
by: Władysław Orłowski, et al.
Published: (2023)

USE OF GLP-1 RECEPTOR AGONISTS AND/OR SGLT-2 INHIBITORS AMONG PATIENTS WITH PERIPHERAL ARTERY DISEASE BEFORE AND AFTER REVASCULARIZATION IN A SINGLE-CENTER COHORT
by: Franck H. Azobou Tonleu, MD
Published: (2024)

Impact of socioeconomic position on initiation of SGLT-2 inhibitors or GLP-1 receptor agonists in patients with type 2 diabetes - a Danish nationwide observational study
by: Alexander C. Falkentoft, et al.
Published: (2022)

Influence of the combination of SGLT2 inhibitors and GLP-1 receptor agonists on eGFR decline in type 2 diabetes: post-hoc analysis of RECAP study
by: Yoshimi Muta, et al.
Published: (2024)

The Efficacy and Safety of the Combination Therapy With GLP-1 Receptor Agonists and SGLT-2 Inhibitors in Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis
by: Chen Li, et al.
Published: (2022)

Impact of Initiating a GLP1 Agonist and/or SGLT2 Inhibitor Therapy on De-Escalation and Discontinuation of Insulin and Diabetes Control When Managed by an Interprofessional Collaborative Team
by: Megan Champion, et al.
Published: (2024)

Healthcare professionals' perceptions and management of obesity & knowledge of glucagon, GLP‐1, GIP receptor agonists, and dual agonists
by: W. Timothy Garvey, et al.
Published: (2024)

Risk of lower limb amputation in diabetic patients using SGLT2 inhibitors DPP4 inhibitors or GLP-1 agonists: a meta-analysis of 2 million patients
by: Yang Lu, et al.
Published: (2023)

Population pharmacokinetics of the GIP/GLP receptor agonist tirzepatide
by: Karen Schneck, et al.
Published: (2024)

Danuglipron - an innovate GLP agonist - literature short review
by: Agata Frańczuk, et al.
Published: (2024)

Safety of SGLT2 inhibitors, DPP-4 inhibitors, and GLP-1 receptor agonists in US veterans with and without chronic kidney disease: a population-based studyResearch in context
by: Yoko Narasaki, et al.
Published: (2024)

INITIATING PATIENTS ON GLP-1/COMBINED GLP-1 AND GIP AGONISTS: A QUALITY IMPROVEMENT PROJECT
by: Shreya Srivastava, MD, MPH
Published: (2024)

GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art
by: Michael A. Nauck, et al.
Published: (2021)

GLP-1 receptor agonists and myocardial metabolism in atrial fibrillation
by: Jiani Zhong, et al.
Published: (2024)

Retatrutide - revolutionary recently developed GLP agonist - literature review
by: Patrycja Brzozowska, et al.
Published: (2024)

Impact of GLP-1 Receptor Agonists on Psoriasis and Cardiovascular Comorbidities: A Narrative Review
by: Haran K, et al.
Published: (2024)

Phytomedicine as a source of SGLT2 inhibitors, GLP-1 secretagogues and DPP-IV inhibitors for mitigation of Diabetic Nephropathy
by: Anuj Kumar Borah, et al.
Published: (2022)

Glucagon-like peptide-1 (GLP-1) agonists in the treatment of obesity
by: Magdalena Mazurek, et al.
Published: (2023)

The Impact of GLP-1 Agonists on Depression Treatment: A Literature Review
by: Paulina Lemieszek, et al.
Published: (2024)

GLP-1 Receptor Agonists and Coronary Arteries: From Mechanisms to Events
by: Aurélie Pahud de Mortanges, et al.
Published: (2022)

A potentially serious adverse effect of GLP-1 receptor agonists
by: Jinmiao Lu, et al.
Published: (2023)

The Use of GLP-1 Receptor Agonists in the Treatment of Obesity in Women with PCOS
by: Aleksandra Jaroń, et al.
Published: (2024)

GLP-1 Receptor Agonists in the Treatment of Patients with Type 2 Diabetes and Chronic Kidney Disease
by: Joshua J. Neumiller, et al.
Published: (2022)

Designing a Dual GLP-1R/GIPR Agonist from Tirzepatide: Comparing Residues Between Tirzepatide, GLP-1, and GIP
by: Wang L
Published: (2022)

Pharmacovigilance study of GLP-1 receptor agonists for metabolic and nutritional adverse events
by: Long He, et al.
Published: (2024)

SGLT2i and GLP1-RA exert additive cardiorenal protection with a RAS blocker in uninephrectomized db/db mice
by: Nerea Martos-Guillami, et al.
Published: (2024)

A meta-analysis of the incidence of acne vulgaris in patients treated with GLP-1 agonists
by: Oluwafunke O. Ogunremi, BS, et al.
Published: (2024)

Timing of GLP-1 Receptor Agonist Initiation for Treatment of Type 2 Diabetes in the UK
by: Kristina S. Boye, et al.
Published: (2019)

GLP-1 Receptor Agonists in Diabetic Kidney Disease: From Clinical Outcomes to Mechanisms
by: Daiji Kawanami, et al.
Published: (2020)

A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond
by: Lalita Prasad-Reddy, et al.
Published: (2015)

Development of Syringaldehyde as an Agonist of the GLP-1 Receptor to Alleviate Diabetic Disorders in Animal Models
by: Jenpei Lee, et al.
Published: (2024)

Effect of GLP-1 Receptor Agonist on Ischemia Reperfusion Injury in Rats with Metabolic Syndrome
by: Marko Ravic, et al.
Published: (2024)

GLP-1 receptor agonists in diabetic kidney disease: current evidence and future directions
by: Ji Hee Yu, et al.
Published: (2022)

Obesity medication lorcaserin activates brainstem GLP-1 neurons to reduce food intake and augments GLP-1 receptor agonist induced appetite suppression
by: Stefan Wagner, et al.
Published: (2023)

Partial agonism improves the anti-hyperglycaemic efficacy of an oxyntomodulin-derived GLP-1R/GCGR co-agonist
by: Phil Pickford, et al.
Published: (2021)

The development of an oral GLP-1 receptor agonist for the management of type 2 diabetes: evidence to date
by: Antza C, et al.
Published: (2019)

GLP-1 Receptor Agonists: A Promising Therapy for Modern Lifestyle Diseases with Unforeseen Challenges
by: Patrycja Kupnicka, et al.
Published: (2024)